Procarbazine
| Evidence Level: L3 | Predicted Indications: 5 |
Table of Contents
- Procarbazine
- Pharmacist Assessment Report
- Procarbazine: From Hodgkin Lymphoma to Follicular Lymphoma
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Cytotoxicity
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Procarbazine: From Hodgkin Lymphoma to Follicular Lymphoma
One-Sentence Summary
Procarbazine is an oral alkylating-type chemotherapy agent, originally used to treat Hodgkin lymphoma. The TxGNN model predicts it may be effective for follicular lymphoma, with 2 related clinical trials (neither directly testing procarbazine) and 12 publications currently supporting this direction, mostly older reports and small case series.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hodgkin lymphoma (including classic Hodgkin lymphoma and related subtypes) |
| Predicted New Indication | Follicular lymphoma |
| TxGNN Prediction Score | 0.9946 |
| Evidence Level | L3 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, procarbazine is an oral alkylating-type agent with activity against lymphoma. Its efficacy in Hodgkin lymphoma is established, and mechanistically it may be applicable to follicular lymphoma.
Hodgkin lymphoma and follicular lymphoma are both lymphoid malignancies, and procarbazine’s cytotoxic activity against lymphoid cells provides biological plausibility. Procarbazine has also been used historically in non-Hodgkin lymphoma. One report describes two patients with relapsed or refractory follicular lymphoma who achieved a complete and durable remission with a prolonged course of daily procarbazine (PMID 16690522). A low-dose oral metronomic regimen containing procarbazine (PEP-C) has also been tested in relapsed or refractory lymphoma.
There is an important caveat. Current follicular lymphoma standards are anti-CD20 based, so procarbazine’s role would be at most a niche salvage or combination component.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00003113 | Phase 2 | Terminated | 6 | Oral combination chemotherapy with G-CSF in elderly patients with intermediate- or high-grade non-Hodgkin lymphoma. Terminated after only 6 participants, so it gives almost no usable efficacy evidence. The regimen composition is not confirmed. |
| NCT00577993 | Phase 3 | Completed | 210 | Fludarabine, mitoxantrone and dexamethasone plus rituximab in stage IV indolent lymphoma. The regimen does not include procarbazine, so it serves only as disease-context information. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 16690522 | 2006 | Review (case report) | Leukemia & Lymphoma | Two patients with relapsed or refractory follicular lymphoma achieved a complete and durable remission with prolonged daily procarbazine |
| 11672513 | 2001 | RCT | J Hematother Stem Cell Res | Chemotherapy plus interferon-alpha2b versus chemotherapy alone in follicular lymphoma (not procarbazine-specific) |
| 22507790 | 2012 | Cohort | Hematology | PEP-C low-dose oral metronomic combination chemotherapy for refractory or relapsed lymphoma |
| 16230674 | 2005 | Review | J Clin Oncol | New treatment options have changed survival of patients with follicular lymphoma |
| 1702144 | 1991 | Randomized trial | J Clin Oncol | ProMACE-CytaBOM versus ProMACE-MOPP (procarbazine-containing) in advanced diffuse aggressive lymphoma, which included some follicular large-cell cases |
| 6370065 | 1984 | Clinical series | Ann Intern Med | Prolonged initial remission in 79 patients with nodular mixed lymphoma treated with various regimens |
| 8426197 | 1993 | Cohort | J Clin Oncol | Clinical features and prognosis of follicular large-cell lymphoma |
| 6366124 | 1983 | Review | J Clin Oncol | Histologic conversion in non-Hodgkin lymphomas |
| 2788716 | 1989 | Cohort | J Clin Oncol | Combination chemotherapy followed by involved-field radiation in localized aggressive lymphomas |
| 19654036 | 2009 | Cohort | Exp Hematol | Fludarabine-induced myelotoxicity in 100 follicular lymphoma patients (not procarbazine-specific) |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 00012750 | MATULANE | Not specified | Not specified |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (alkylating-type agent) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions. The knowledge graph links procarbazine with contraindications such as thrombocytopenia, leukopenia and anemia, which points to haematological toxicity. |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Complete blood count with platelets, liver and renal function |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Safety Considerations
- Contraindications (not label text): liver failure, liver disease, kidney disease, gallbladder disease, thrombocytopenia, leukopenia, anemia (including macrocytic anemia), blood coagulation disease, peripheral neuropathy and other peripheral nervous system disease, infectious disease (including fungal infection and dermatophytosis), pyoureter, and substance abuse or dependence.
- Drug Interactions: 100 interactions were identified in total. The main ones are classed as Major, and include:
- Sympathomimetics and stimulants/anorectics: isometheptene, ephedrine, phentermine, diethylpropion, mazindol
- Serotonergic agents: bupropion, lorcaserin, fenfluramine, dexfenfluramine
- Opioid: morphine
- 5-HT3 antagonists: ondansetron, granisetron, palonosetron, dolasetron
Moderate interactions include epinephrine (in several forms), ephedrine (nasal) and metoclopramide. Levofloxacin is Minor.
- Other signals from the literature: procarbazine-containing regimens are associated with gonadotoxicity (such as azoospermia and ovarian failure), and animal bioassays show carcinogenicity.
Official warnings and contraindications from the Canadian package insert were not available and should be reviewed.
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence consists of small case reports, older chemotherapy-combination studies and one terminated Phase 2 trial with only 6 participants. No trial directly tests procarbazine in follicular lymphoma. Modern anti-CD20-based therapy is the standard of care, and procarbazine carries notable toxicity (myelosuppression, gonadotoxicity, secondary malignancy, and many serious drug interactions). The prediction is best treated as a research question for now.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data
- Identification of the regimen and histology in NCT00003113, and a review of PEP-C outcomes in follicular lymphoma
- Comparison against current anti-CD20-based standards to define any niche salvage role
- A safety-monitoring and drug-interaction management plan
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.